Futura Medical confirms Europe launch of MED3000; awaits FDA approval

(Alliance News) - Futura Medical PLC on Tuesday said its MED3000 product is now available online ...

Alliance News 14 March, 2023 | 2:33PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Futura Medical PLC on Tuesday said its MED3000 product is now available online in Europe under the brand name Erexon.

The sexual health-focused pharmaceutical company, based in Surrey, England, said Erexon will also be available to buy in pharmacies in Belgium as of April.

This comes after Futura Medical announced a licensing agreement with Cooper Consumer Health last year for the rights to commercialise MED3000 in Europe, Switzerland and the UK.

MED3000 is a gel developed by Futura Medical used to treat erectile dysfunction.

The company also said it applied for US marketing authorisation for MED3000, which is undergoing a review. The US Food and Drug Administration has asked questions on MED3000, which Futura Medical plans to respond to at the end of the month.

Chief Executive Officer James Barder said the company expects to be granted market authorisation by the FDA in the second half of 2023.

If successful, MED3000 would become the first globally available, clinically proven, over the counter treatment for erectile dysfunction.

Shares were down 3.8% at 48.19 pence in London on Tuesday afternoon.

By Sabrina Penty; Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Futura Medical PLC 40.15 GBX 0.37 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures